




RealRate

PHARMACEUTICAL 2021

Molecular Templates Inc.
Rank 310 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

Molecular Templates Inc. Rank 310 of 409

The relative strengths and weaknesses of Molecular Templates Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Molecular Templates Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 68% points. The greatest weakness of Molecular Templates Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 183% points.

The company's Economic Capital Ratio, given in the ranking table, is -327%, being 27% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	101,324
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	37,553
Liabilities, Non-Current	28,629
Other Assets	16,299
Other Compr. Net Income	0
Other Expenses	1,710
Other Liabilities	14,355
Other Net Income	16,481
Property and Equipment	22,254
Research and Development	92,965
Revenues	0
Selling, General and Administrative Expense	26,722

Output Variable	Value in 1000 USD
Assets	139,877
Liabilities	80,537
Expenses	121,397
Stockholders Equity	59,340
Net Income	-104,916
Comprehensive Net Income	-104,916
Economic Capital Ratio	-327%

